Advertisement Wilshire confirms first-to-file patent challenge relating to LASTACAFT - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Wilshire confirms first-to-file patent challenge relating to LASTACAFT

Wilshire Pharmaceuticals, confirmed that it has been sued by Allergan and Vistakon Pharmaceuticals in connection with Wilshire's filing of an Abbreviated New Drug Application with the US Food and Drug Administration for Alcaftadine (alcaftadine ophthalmic solution) 0.25%.

This product is the generic version of LASTACAFT (alcaftadine ophthalmic solution) 0.25%, which is indicated for the prevention of itching associated with allergic conjunctivitis.

Wilshire believes that it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity upon receiving final FDA approval.

Wilshire’s President, Scott White, stated, "We are excited about the continued development of our pipeline, and Alcaftadine represents another key milestone for Wilshire. This filing affirms Wilshire’s commitment to bringing affordable, quality medicines to patients who need them."

Wilshire, headquartered in Atlanta, Georgia, is a wholly owned subsidiary of Arbor Pharmaceuticals, LLC. Wilshire is a generic pharmaceutical company focused on developing select generic pharmaceutical products.

In addition to its extensive pipeline, the company continues to actively pursue growth through acquisition and product development opportunities.